Sinopharm and Biomedical Engineering Institute finalized reorganization is expec
Group Corporation (the "Sinopharm") re-integration of Shanghai Pharmaceutical (600,849, stock it) Industrial Technology Research Institute (the "Biomedical Engineering Institute"), is expected to be announced in May this year, the official news. Some analysts said the hospital's medical engineering as the only listed company?? Modern
Pharmacy (600,420, stock it) is expected to benefit from the restructuring of the Sinopharm. Yesterday, the modern pharmaceutical (600,420, stock it) told New Express reporter, said, "If the reorganization is successful, the company will be more good than harm." Another report shows that Yawei the third quarter of last year already on the "latent" Among the stock.
A month later re-released Yesterday, Zhi-Ping Song, chairman of the first position Sinopharm said Sinopharm and Biomedical Engineering Institute of the reorganization and integration, in the "two sessions" SASAC after signing his words, one month after the formal announcement is expected. This means hospital doctors work is expected before May this year into Sinopharm.
It is understood, Biomedical Engineering Institute, 2008
Sell Income of 910 million yuan, two affiliated industrial enterprises: the modern pharmaceutical and Shanghai Modern Pharmaceutical Research Center Limited ("preparation center").
Fact, Sinopharm and Biomedical Engineering Institute of the reorganization and integration has been heated debate about the uproar last year, the market is expected to acquire medical engineering Sinopharm the hospital, will be the platform of modern drug development in the field of chemical medicine. Another market that in 2006 the implementation of modern pharmaceutical split share structure reform, the Biomedical Engineering Institute has pledged to focus on supporting the development of modern pharmaceuticals, at the appropriate time, the quality of its own assets in an appropriate way into the modern pharmaceutical . Who share this view that day care, medical workers there may be agents Centre Court into the company. If the company can successfully integrate preparation center, central reserve agents can be injected directly into the company of new varieties, will enrich the existing product line. Biomedical Engineering Dean also clear last year, "to strengthen and expand the basis of listed companies to plan the overall market," one of the priorities for the five years, the overall market will start pre-planning.
For restructuring and asset Sinopharm injection of modern pharmaceutical securities yesterday, the staff told reporters, "There has not officially announced reorganization of the results, I can not comment. Can only say now restructuring is successful, the company more advantages than disadvantages. assets into the market is just hearsay, subject to all matters have been announced. "
Yawei rate "China Department" latent
Restructuring and asset injection as well expected, but also to institutional investors, much of modern pharmaceutical concern, which Yawei early third quarter of last year had "hidden" one, the season average price of 11.53 yuan. The latest report shows that the top ten outstanding shares of the Fund accounted for six seats, including "Chinese line" account for half of the country, in charge of China by the Yawei tape (000,011, fund it) Although the third quarter compared with holdings of 19 million shares, but 631.22 million shares still in circulation out of the top ten shareholders of the eighth. The other with in the third quarter dividend in the column of China (002011, fund it), sending out small cap (162,703, fund it) no change in the Fund, another "Chinese line" fund China steady growth (519029, fund it ) are large-scale holdings to 667.97 million shares, shareholders in one fell swoop as the seventh largest in circulation.
Chips, the shareholders of a few have continued to decline for four consecutive quarters, chips tends to be "very focused." Although the gains since last year have been larger, but no bodies have been obvious signs of escape, turnover has been maintained at below 5%. Some analysts said the stock had 50-day moving average has been to build up channels for the next track. Despite the recent showing a continuous adjustment, but stock prices close to 2 month low, beneath the 50-day moving average, rising into the bottom of the channel location, technical rebound is possible. Also, if the overall market success of the company, then the current less than 300 million equity shares of the dishes there are also more space. So the recent row callback or a better time to buy.
In addition, the annual report, in 2009 the gross revenues of modern pharmaceutical completed 1.164 billion yuan, up 41.10 percent over the same period the previous year; complete full year net profit of 89.0523 million yuan, up 49.87 percent over the same period the previous year; earnings per share 0.31 yuan, up 49.87 percent, the indicators are more substantial than last year's growth.
Yesterday, down 3.12% of modern pharmaceuticals, to close at 14.59 yuan.
We are high quality suppliers, our products such as Hydraulic Drilling Rig , Drilling Tools for oversee buyer. To know more, please visits Core Drilling Rig.
Processing your request, Please wait....
